An observational study in Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus and Fibromyalgia, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Open to participants aged 5 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Children's National Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.
Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 21st largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2021, is one of 24 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 86th registered.
365 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 35
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 5 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 18 · Phase 3 32 · Phase 4 7
First in 1994; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 120 across 118 observational studies indexed under Arthritis, Juvenile.
Median enrollment 55 across the 83 interventional studies, 288 across the 24 observational. Of the 75 that completed or were terminated, 46 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 109 have an industry lead sponsor. The 10 most frequent:
Children's National Research Institute is the lead sponsor of 127 studies on the registry; 47 are open to participants now.
Children's National Research Institute has 1 study filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Juvenile with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 109 studies in Arthritis, Juvenile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups. As this is observational, there is no randomization or blinding in the study. Patients will be followed for a period of one year after enrollment. Baseline measurements will be taken at the time of enrollment, and at each subsequent standard of care clinic visit as feasible, for a period of one year. As this is an observational study, there will be no change to the treatment for any patient due to research activities. The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations. The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.
30 subjects from each of the three populations of interest will be enrolled for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible for inclusion in the study, an individual must meet all of the following criteria:
Exclusion Criteria:
Any individual who meets any of the following criteria will be excluded from participation in this study:
Patients ages 5-21 with a diagnosis of JIA.
Other: No Intervention
Patients ages 5-21 with a diagnosis of SLE.
Other: No Intervention
Patients ages 5-21 with a diagnosis of FM.
Other: No Intervention
No Intervention
Index Characterization
The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations.
Time frame: 1 Year
Treatment Effect
The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.
Time frame: 1 Year
Started Jul 2021 (actual). Primary completion is estimated for Apr 2028, 81 months after the start.
Of 42 observational studies under Arthritis, Juvenile, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 186. This study's planned 81 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's National Research Institute →